---
title: "MCDC Award $20 Million Contract for Development of Auto-Injector"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/mcdc-award-20-million-contract-for-development-of-auto-injector"
date: "2026-07-30T21:52:49+00:00"
language: "en-GB"
---

![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2Fsponsors%2Femergent-biosol-web.jpg%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=adbd5fc4)

#  MCDC Award $20 Million Contract for Development of Auto-Injector

 Written by Zoe Rutherford on 27 September 2019.

Emergent BioSolutions Inc. announced on September 25th that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being designed for intramuscular buddy-administration for use in military environments and for civilian emergencies.

Doug White, SVP and devices business unit head at Emergent BioSolutions, stated, “Emergent is pleased with this follow-on contract, which expands our opportunities to serve the needs of the Department of Defense (DoD) for modern and reliable auto-injectors to protect our military personnel against nerve agents. We are committed to meeting our customers’ high expectations and leverage our more than 20-year history of successfully partnering with governments in addressing public health threats.”

Under the multiple year agreement, awarded through the Medical CBRN Defense Consortium (MCDC), Emergent will develop a device, conduct studies to demonstrate consistent manufacturing, functionality, and usability of the final device, and complete regulatory activities required to obtain approval of the combination product by the U.S. Food and Drug Administration (FDA).

The MCDC was established by the Joint Project Manager for Medical Countermeasure Systems. It is a DoD initiative within the Joint Program Executive Office for Chemical and Biological Defense that provides U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats.

 [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Chemical](https://cbrneworld.com/component/tags/tag/chemical), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Contract](https://cbrneworld.com/component/tags/tag/contract)

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "MCDC Award $20 Million Contract for Development of Auto-Injector", "item": "https://cbrneworld.com/news/subscribers/mcdc-award-20-million-contract-for-development-of-auto-injector" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/mcdc-award-20-million-contract-for-development-of-auto-injector" }, "headline": "MCDC Award $20 Million Contract for Development of Auto-Injector", "description": "Emergent BioSolutions Inc.  announced on September 25th that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being designed for intramuscular buddy-administration for use in military environments and for civilian emergencies. Doug White, SVP and devices business unit head at Emergent BioSolutions, stated, “Emergent is pleased with this follow-on contract, which expands our opportunities to serve the needs of the Department of Defense (DoD) for modern and reliable auto-injectors to protect our military personnel against nerve agents. We are committed to meeting our customers’ high expectations and leverage our more than 20-year history of successfully partnering with governments in addressing public health threats.” Under the multiple year agreement, awarded through the Medical CBRN Defense Consortium (MCDC), Emergent will develop a device, conduct studies to demonstrate consistent manufacturing, functionality, and usability of the final device, and complete regulatory activities required to obtain approval of the combination product by the U.S. Food and Drug Administration (FDA). The MCDC was established by the Joint Project Manager for Medical Countermeasure Systems. It is a DoD initiative within the Joint Program Executive Office for Chemical and Biological Defense that provides U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats.", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/sponsors/emergent-biosol-web.jpg" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Zoe Rutherford", "url": "https://cbrneworld.com/news/subscribers/mcdc-award-20-million-contract-for-development-of-auto-injector" }, "datePublished": "2019-09-27T17:10:52+01:00", "dateCreated": "2019-09-27T17:10:52+01:00", "dateModified": "2019-10-01T13:48:54+01:00" }
```